Note 26 - Segment Information

12 Months Ended

Dec. 31, 2016

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

26—SEGMENT

INFORMATION

The Company currently has

four

reporting segments: the corporate activities of the holding Company, EDAP TMS S.A., the High Intensity Focused Ultrasound division, the Urological Devices and Services division and a reporting segment dedicated to the FDA approval for Ablatherm-HIFU activity. Following the Ablatherm FDA clearance received on

November

9,

2015,

there is no more cost recorded on the FDA segment in

2016.

The following tables set forth the key income statement figures, by segment for fiscal years

2016,

2015

and

2014

and the key balance sheet figures, by segment, for fiscal years

2016,

2015

and

2014.

The business in which the Company operates is the development and production of minimally invasive medical devices, primarily for the treatment of urological diseases. Substantially all revenues result from the sale of medical devices and their related license and royalty payments from

third

parties. The segments derive their revenues from this activity.

Segment operating profit or loss and segment assets are determined in accordance with the same policies as those described in the summary of significant accounting policies. Interest income and expense, current and deferred income taxes are not allocated to individual segments. A reconciliation of segment operating profit or loss to consolidated net loss is as follows:

	2016			2015			2014
Segment operating income (loss)		392			488			(1,736	)
Financial income (expense), net		3,949			(2,094	)		1,771
Foreign Currency exchange (losses) gains, net		103			699			(431	)
Other income (expense), net		-			-			-
Income tax (expense) credit		(602	)		(759	)		(116	)
Consolidated net profit (loss)		3,842			(1,667	)		(512	)

A summary of the Company’s operations by segment is presented below for years ending

December

31,

2016,

2015

and

2014:

	HIFU Division			UDS Division			EDAP TMS (Corporate)			FDA		Total consolidated
2016
Sales of goods		9,382			14,664			-			-		24,045
Sales of RPPs & leases		3,547			1,359			-			-		4,906
Sales of spare parts and services		862			5,766			-			-		6,628
Total sales		13,791			21,789			-			-		35,579
External other revenues		28			4			-			-		32
Total revenues		13,819			21,792								35,611
Total COS		(5,710	)		(13,490	)		-			-		(19,200	)
Gross margin		8,109			8,302			-			-		16,411
R&D		(2,452	)		(1,416	)		-			-		(3,868	)
Selling and marketing expenses		(3,888	)		(4,968	)		-			-		(8,856	)
G&A		(804	)		(1,177	)		(1,315	)		-		(3,296	)
Total expenses		(7,144	)		(7,560	)		(1,315	)		1		(16,019	)
Operating income (loss)		964			742			(1,315	)		1		392
Total Assets		11,680			24,202			10,709			-		46,591
Capital expenditures		1,013			608			-			-		1,621
Long-lived assets		1,775			3,812			192			-		5,779
Goodwill		645			1,767			-			-		2,412

	HIFU Division			UDS Division			EDAP TMS (Corporate)			FDA			Total consolidated
2015
Sales of goods		4,878			17,027			-			-			21,906
Sales of RPPs & leases		2,908			1,501			-			-			4,408
Sales of spare parts and services		658			5,246			-			-			5,904
Total sales		8,444			23,774			-			-			32,218
External other revenues		32			3			-			-			35
Total revenues		8,476			23,777			-			-			32,253
Total COS		(3,636	)		(14,832	)		-			-			(18,468	)
Gross margin		4,841			8,945			-			-			13,785
R&D		(1,387	)		(992	)		-			(311	)		(2,690	)
Selling and marketing expenses		(2,284	)		(5,122	)		-						(7,406	)
G&A		(646	)		(1,192	)		(1,363	)					(3,202	)
Total expenses		(4,318	)		(7,306	)		(1,363	)		(311	)		(13,298	)
Operating income (loss)		523			1,639			(1,363	)		(311	)		488
Total Assets		9,619			25,818			3,144			-			38,581
Capital expenditures		457			207			-			-			664
Long-lived assets		1,437			3,320			192			-			4,949
Goodwill		645			1,767			-			-			2,412

	HIFU Division			UDS Division			EDAP TMS (Corporate)			FDA			Total consolidated
2014
Sales of goods		5,270			11,625			-			-			16,895
Sales of RPPs & leases		2,170			1,787			-			-			3,957
Sales of spare parts and services		760			4,640			-			-			5,400
Total sales		8,200			18,052			-			-			26,252
External other revenues		518			15			-			-			533
Total revenues		8,718			18,067			-			-			26,785
Total COS		(3,683	)		(11,901	)		-			-			(15,584	)
Gross margin		5,035			6,166			-			-			11,201
R&D		(1,062	)		(646	)		-			(1,224	)		(2,932	)
Selling and marketing expenses		(2,151	)		(4,527	)		-			-			(6,678	)
G&A		(660	)		(1,153	)		(1,514	)		-			(3,328	)
Total expenses		(3,874	)		(6,326	)		(1,514	)		(1,224	)		(12,937	)
Operating income (loss)		1,162			(160	)		(1,514	)		(1,224	)		(1,736	)
Total Assets		7,468			20,778			3,715			193			32,154
Capital expenditures		464			569			-			-			1,033
Long-lived assets		1,410			3,300			192			-			4,902
Goodwill		645			1,767			-			-			2,412